Director of Berman Institute comments on FDA Approval of first human embryonic stem ...( The report today that the FDA has a...)
Navigation Links
Director of Berman Institute comments on FDA Approval of first human embryonic stem cell trial
Date:1/23/2009
"The report today that the FDA has approved the first human clinical trial of an embryonic stem cell-based intervention raises important ethical considerations, but not only, or even primarily, because what is at issue is an embryonic stem cell-based intervention. Although deep-seated disagreements about the ethics of embryo research surround the interest in this study, we need to focus as well on this being the first human trial of its kind. Any "first in human beings" medical experiment requires the highest level of moral scrutiny and oversight. At this point it is critical that every effort be made to protect the welfare and rights of the patients who will be approached to be these human subjects. A good place to start would be by NOT referring to this study as a trial of a stem cell-based therapy, as Geron has described it, but rather as a stem cell-based intervention whose therapeutic benefits in humans has not yet been studied. It is also important to emphasize that this trial offers little prospect of clinical improvement to the very first patients who will participate in the safety phase of the research."
'/>"/>
| Contact: Ralph Loglisci RalphL@jhu.edu 410-625-7872 Johns Hopkins Berman Institute of Bioethics Source:Eurekalert |
Related biology news :
1. Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors
2. Office of the Director of National Intelligence, CIO to Speak at Government Security Conference
3. Director of National Intelligence to Speak at Conference
4. Office of the Director of National Intelligence, CIO to Speak at Government Security Conference
5. Director of National Intelligence to Speak at Conference
6. Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors
7. Ingram Micro to Distribute New Fujitsu Biometric Login Products for Novell eDirectory in United States
8. Solidus Networks, Inc. Seats New Board of Directors
9. Fujitsu Announces PalmSecure(TM) LOGONDIRECTOR
10. Julia Zeitlinger selected for NIH Directors New Innovator Award
11. bioMETRX, Inc. Welcomes Residential and Commercial Security Expert to Board of Directors
Post Your Comments:
Breaking Biology News(10 mins):Study reveals how Arctic food webs affect mercury in polar bears 2Why King Kong failed to impress 2Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 2Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 3Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 4Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 5Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 6Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 7Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 8Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 9Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 10Discovery of the cells water gate may lead to new cancer drugs 8868 1Discovery of the cells water gate may lead to new cancer drugs 8868 2The Consumers Role in Medication Safety An Interactive Discussion with a Pharmacist on Live TV 49204 1The Consumers Role in Medication Safety An Interactive Discussion with a Pharmacist on Live TV 49204 2Help for Struggling CPAP Users Comes to Sleep HealthCenters in Weymouth 49201 1Help for Struggling CPAP Users Comes to Sleep HealthCenters in Weymouth 49201 2
Other Biology News:New technique could dramatically lower costs of DNA sequencing 2BGSU undergraduates to pilot groundbreaking genome project 2BGSU undergraduates to pilot groundbreaking genome project 3Research unveils new hope for deadly childhood disease 2
Breaking Biology Technology:Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4New antioxidant compounds have been identified in foods such as olive oil, honey and nuts 2Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 2Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 3Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 4PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision 2
[0] Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics[0] New antioxidant compounds have been identified in foods such as olive oil, honey and nuts[0] Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit[0] PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
Other Biology Technology:PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 2PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 3PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 4PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 5PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 6PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 7Pearl Therapeutics Secures $8 Million in Debt Financing 2Pearl Therapeutics Secures $8 Million in Debt Financing 3Novartis/Schering-Plough's Drug Will Replace AstraZeneca's Symbicort as Decision Resources' Clinical Gold Standard by 2012 for the Treatment of Asthma 2
PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense MeetingPearl Therapeutics Secures $8 Million in Debt FinancingNovartis/Schering-Plough's Drug Will Replace AstraZeneca's Symbicort as Decision Resources' Clinical Gold Standard by 2012 for the Treatment of Asthma
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |